Non-Cochrane · prevalence · PM42125052
Anti-Annexin A5 antibodies and Annexin A5 resistance in antiphospholipid syndrome: A systematic review and meta-analysis.
Alamlih Laith, Becetti Karima, Al Emadi Samar, et al. · Journal of translational autoimmunity · 2026 · PubMed · doi:10.1016/j.jtauto.2026.100373
Findings
299 findings
| Population | ||||
|---|---|---|---|---|
| Patients with obstetric APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Population type: Obstetric | Pooled prevalence (%) 29.9 [13.1, 49.9] GRADE not reported 4 studies · 358 participants |
| Patients with obstetric APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Population type: Obstetric | Pooled prevalence (%) 3.1 [1.4, 5.3] GRADE not reported 9 studies · 1671 participants |
| Patients with obstetric APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Population type: Obstetric | Pooled prevalence (%) 21.2 [7.4, 39.2] GRADE not reported 17 studies · 2023 participants |
| Patients with obstetric APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · Population type: Obstetric | Pooled prevalence (%) 14.2 [7.5, 22.3] GRADE not reported 8 studies · 693 participants |
| Patients with obstetric APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, isotype unknown Studies of adults with APS and controls · Population type: Obstetric | Pooled prevalence (%) 8.4 [2.2, 17.4] GRADE not reported 2 studies · 59 participants |
| Patients with thrombotic APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Population type: Thrombosis | Pooled prevalence (%) 10.3 [5.7, 15.8] GRADE not reported 22 studies · 1577 participants |
| Patients with thrombotic APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · Population type: Thrombosis | Pooled prevalence (%) 10.2 [6.5, 14.5] GRADE not reported 5 studies · 385 participants |
| Patients with thrombotic APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Population type: Thrombosis | Pooled prevalence (%) 28.8 [13.2, 47.4] GRADE not reported 5 studies · 672 participants |
| Patients with thrombotic APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Population type: Thrombosis | Pooled prevalence (%) 4.6 [0.4, 12.1] GRADE not reported 12 studies · 1100 participants |
| Patients with APS of any phenotype (obstetric, thrombosis, mixed) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Population type: Mixed | Pooled prevalence (%) 41.0 [24.5, 58.5] GRADE not reported 12 studies · 1256 participants |
| Patients with APS of any phenotype (obstetric, thrombosis, mixed) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, isotype unknown Studies of adults with APS and controls · Population type: Mixed | Pooled prevalence (%) 2.6 [0.0, 8.6] GRADE not reported 4 studies · 217 participants |
| Patients with APS of any phenotype (obstetric, thrombosis, mixed) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · Population type: Mixed | Pooled prevalence (%) 17.3 [9.8, 26.2] GRADE not reported 15 studies · 1253 participants |
| Patients with APS of any phenotype (obstetric, thrombosis, mixed) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Population type: Mixed | Pooled prevalence (%) 18.3 [12.1, 25.4] GRADE not reported 54 studies · 4429 participants |
| Patients with APS of any phenotype (obstetric, thrombosis, mixed) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Population type: Mixed | Pooled prevalence (%) 5.7 [2.9, 9.3] GRADE not reported 30 studies · 3417 participants |
| Controls | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Population type: Control | Pooled prevalence (%) 4.0 [1.7, 7.1] GRADE not reported 27 studies · 1542 participants |
| Controls | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Population type: Control | Pooled prevalence (%) 3.1 [0.9, 6.2] GRADE not reported 14 studies · 960 participants |
| Controls | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, isotype unknown Studies of adults with APS and controls · Population type: Control | Pooled prevalence (%) 1.9 [0.0, 8.1] GRADE not reported 2 studies · 100 participants |
| Controls | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Population type: Control | Pooled prevalence (%) 17.5 [7.8, 29.7] GRADE not reported 8 studies · 563 participants |
| Controls | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · Population type: Control | Pooled prevalence (%) 26.6 [4.1, 58.1] GRADE not reported 3 studies · 184 participants |
| Patients with seropositive APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · APS status: Seropositive | Pooled prevalence (%) 27.1 [16.5, 39.0] GRADE not reported 19 studies · 1018 participants |
| Patients with seropositive APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · APS status: Seropositive | Pooled prevalence (%) 58.4 [38.3, 77.3] GRADE not reported 7 studies · 533 participants |
| Patients with seropositive APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · APS status: Seropositive | Pooled prevalence (%) 10.6 [4.9, 18.0] GRADE not reported 13 studies · 767 participants |
| Patients with seronegative APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · APS status: Seronegative | Pooled prevalence (%) 20.4 [1.3, 50.9] GRADE not reported 8 studies · 252 participants |
| Patients with seronegative APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · APS status: Seronegative | Pooled prevalence (%) 13.2 [9.7, 17.1] GRADE not reported 3 studies · 503 participants |
| Patients with seronegative APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · APS status: Seronegative | Pooled prevalence (%) 34.7 [19.1, 52.0] GRADE not reported 2 studies · 117 participants |
| Patients with seronegative APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · APS status: Seronegative | Pooled prevalence (%) 11.3 [0.0, 51.4] GRADE not reported 3 studies · 75 participants |
| Patients with APS of mixed or unstratified serologic status | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, isotype unknown Studies of adults with APS and controls · APS status: Mixed | Pooled prevalence (%) 4.1 [0.0, 12.9] GRADE not reported 3 studies · 181 participants |
| Patients with APS of mixed or unstratified serologic status | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · APS status: Mixed | Pooled prevalence (%) 11.7 [5.9, 18.8] GRADE not reported 30 studies · 3305 participants |
| Patients with APS of mixed or unstratified serologic status | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · APS status: Mixed | Pooled prevalence (%) 14.5 [8.4, 21.7] GRADE not reported 14 studies · 1193 participants |
| Patients with APS of mixed or unstratified serologic status | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · APS status: Mixed | Pooled prevalence (%) 24.6 [7.2, 47.8] GRADE not reported 3 studies · 366 participants |
| Patients with APS of mixed or unstratified serologic status | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · APS status: Mixed | Pooled prevalence (%) 2.0 [1.0, 3.3] GRADE not reported 16 studies · 2705 participants |
| Controls (APS status analysis, includes seropositive controls) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · APS status: Control | Pooled prevalence (%) 3.6 [1.0, 7.4] GRADE not reported 12 studies · 830 participants |
| Controls (APS status analysis, includes seropositive controls) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · APS status: Control | Pooled prevalence (%) 3.9 [1.6, 6.9] GRADE not reported 24 studies · 1396 participants |
| Controls (APS status analysis, includes seropositive controls) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, isotype unknown Studies of adults with APS and controls · APS status: Control | Pooled prevalence (%) 1.9 [0.0, 8.1] GRADE not reported 2 studies · 100 participants |
| Controls (APS status analysis, includes seropositive controls) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · APS status: Control | Pooled prevalence (%) 18.5 [7.2, 33.1] GRADE not reported 7 studies · 417 participants |
| Patients with SLE and APS clinical manifestations | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Autoimmune disorder: SLE | Pooled prevalence (%) 52.0 [0.0, 100.0] GRADE not reported 2 studies · 160 participants |
| Patients with SLE and APS clinical manifestations | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Autoimmune disorder: SLE | Pooled prevalence (%) 31.7 [19.8, 44.7] GRADE not reported 8 studies · 195 participants |
| Patients with APS and mixed autoimmune status | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · Autoimmune disorder: Mixed | Pooled prevalence (%) 19.8 [11.5, 29.6] GRADE not reported 13 studies · 1162 participants |
| Patients with APS and mixed autoimmune status | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, isotype unknown Studies of adults with APS and controls · Autoimmune disorder: Mixed | Pooled prevalence (%) 2.6 [0.0, 8.6] GRADE not reported 4 studies · 217 participants |
| Patients with APS and mixed autoimmune status | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Autoimmune disorder: Mixed | Pooled prevalence (%) 6.0 [2.4, 10.8] GRADE not reported 18 studies · 1839 participants |
| Patients with APS and mixed autoimmune status | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Autoimmune disorder: Mixed | Pooled prevalence (%) 18.2 [10.1, 27.9] GRADE not reported 31 studies · 2365 participants |
| Patients with APS and mixed autoimmune status | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Autoimmune disorder: Mixed | Pooled prevalence (%) 37.9 [17.7, 60.4] GRADE not reported 8 studies · 976 participants |
| Patients with APS and no autoimmune disease | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Autoimmune disorder: No autoimmune disease | Pooled prevalence (%) 46.0 [35.9, 56.3] GRADE not reported 2 studies · 120 participants |
| Patients with APS and no autoimmune disease | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · Autoimmune disorder: No autoimmune disease | Pooled prevalence (%) 4.1 [0.2, 11.0] GRADE not reported 2 studies · 91 participants |
| Patients with APS and no autoimmune disease | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Autoimmune disorder: No autoimmune disease | Pooled prevalence (%) 12.7 [3.5, 25.9] GRADE not reported 15 studies · 1869 participants |
| Patients with APS and no autoimmune disease | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Autoimmune disorder: No autoimmune disease | Pooled prevalence (%) 5.5 [1.4, 11.5] GRADE not reported 12 studies · 1578 participants |
| Controls with rheumatoid arthritis | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Autoimmune disorder: Control-RA | Pooled prevalence (%) 14.7 [1.4, 35.2] GRADE not reported 2 studies · 20 participants |
| Controls with SLE | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Autoimmune disorder: Control-SLE | Pooled prevalence (%) 29.8 [9.9, 54.6] GRADE not reported 3 studies · 232 participants |
| Controls with SLE | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Autoimmune disorder: Control-SLE | Pooled prevalence (%) 16.3 [11.4, 21.8] GRADE not reported 3 studies · 209 participants |
| Controls with no autoimmune disease | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Autoimmune disorder: Control-no autoimmune disease | Pooled prevalence (%) 16.4 [0.0, 58.4] GRADE not reported 2 studies · 65 participants |
| Controls with no autoimmune disease | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Autoimmune disorder: Control-no autoimmune disease | Pooled prevalence (%) 1.9 [0.0, 5.9] GRADE not reported 6 studies · 257 participants |
| Controls with no autoimmune disease | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Autoimmune disorder: Control-no autoimmune disease | Pooled prevalence (%) 1.2 [0.0, 3.2] GRADE not reported 10 studies · 506 participants |
| Controls with RA and SLE | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Autoimmune disorder: Control-RA and SLE | Pooled prevalence (%) 29.8 [9.9, 54.6] GRADE not reported 3 studies · 232 participants |
| Controls with RA and SLE | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Autoimmune disorder: Control-RA and SLE | Pooled prevalence (%) 15.5 [10.7, 20.8] GRADE not reported 5 studies · 229 participants |
| Patients with Sapporo-defined obstetric APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Pregnancy type: Sapporo | Pooled prevalence (%) 71.5 [15.3, 100.0] GRADE not reported 2 studies · 136 participants |
| Patients with Sapporo-defined obstetric APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Pregnancy type: Sapporo | Pooled prevalence (%) 31.0 [17.0, 46.9] GRADE not reported 20 studies · 1031 participants |
| Patients with Sapporo-defined obstetric APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · Pregnancy type: Sapporo | Pooled prevalence (%) 55.8 [32.6, 77.7] GRADE not reported 2 studies · 175 participants |
| Patients with Sapporo-defined obstetric APS | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Pregnancy type: Sapporo | Pooled prevalence (%) 9.9 [4.2, 17.5] GRADE not reported 10 studies · 676 participants |
| Women with recurrent abortion not meeting Sapporo criteria | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Pregnancy type: Recurrent abortions (not Sapporo) | Pooled prevalence (%) 41.3 [16.5, 68.5] GRADE not reported 5 studies · 448 participants |
| Women with recurrent abortion not meeting Sapporo criteria | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · Pregnancy type: Recurrent abortions (not Sapporo) | Pooled prevalence (%) 13.5 [6.4, 22.5] GRADE not reported 7 studies · 663 participants |
| Women with recurrent abortion not meeting Sapporo criteria | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Pregnancy type: Recurrent abortions (not Sapporo) | Pooled prevalence (%) 3.2 [1.4, 5.5] GRADE not reported 8 studies · 1641 participants |
| Women with recurrent abortion not meeting Sapporo criteria | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Pregnancy type: Recurrent abortions (not Sapporo) | Pooled prevalence (%) 13.1 [2.9, 28.6] GRADE not reported 11 studies · 1810 participants |
| Patients with arterial thrombosis | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Thrombosis type: Arterial | Pooled prevalence (%) 0.0 [0.0, 1.1] GRADE not reported 3 studies · 320 participants |
| Patients with arterial thrombosis | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Thrombosis type: Arterial | Pooled prevalence (%) 5.8 [0.4, 15.5] GRADE not reported 6 studies · 594 participants |
| Patients with arterial thrombosis (stroke) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Thrombosis type: Arterial-stroke | Pooled prevalence (%) 4.3 [0.0, 13.9] GRADE not reported 3 studies · 480 participants |
| Patients with arterial thrombosis (stroke) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Thrombosis type: Arterial-stroke | Pooled prevalence (%) 0.0 [0.0, 0.6] GRADE not reported 2 studies · 293 participants |
| Patients with venous thrombosis | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Thrombosis type: Venous | Pooled prevalence (%) 16.1 [7.4, 27.0] GRADE not reported 5 studies · 263 participants |
| Patients with venous thrombosis | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Thrombosis type: Venous | Pooled prevalence (%) 2.9 [0.1, 7.8] GRADE not reported 4 studies · 244 participants |
| Patients with venous thrombosis | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · Thrombosis type: Venous | Pooled prevalence (%) 11.6 [3.5, 23.5] GRADE not reported 2 studies · 216 participants |
| Patients with thrombotic APS of any type (arterial, venous, mixed) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgG anti-Annexin A5 antibodies Studies of adults with APS and controls · Thrombosis type: Mixed | Pooled prevalence (%) 17.1 [11.0, 24.1] GRADE not reported 37 studies · 2406 participants |
| Patients with thrombotic APS of any type (arterial, venous, mixed) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of Annexin A5 resistance (A5R) Studies of adults with APS and controls · Thrombosis type: Mixed | Pooled prevalence (%) 38.4 [19.7, 59.0] GRADE not reported 7 studies · 832 participants |
| Patients with thrombotic APS of any type (arterial, venous, mixed) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, isotype unknown Studies of adults with APS and controls · Thrombosis type: Mixed | Pooled prevalence (%) 0.4 [0.0, 2.5] GRADE not reported 2 studies · 158 participants |
| Patients with thrombotic APS of any type (arterial, venous, mixed) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of anti-Annexin A5 antibodies, IgG/IgM/IgA combined Studies of adults with APS and controls · Thrombosis type: Mixed | Pooled prevalence (%) 21.0 [7.3, 39.0] GRADE not reported 7 studies · 560 participants |
| Patients with thrombotic APS of any type (arterial, venous, mixed) | Testing for anti-Annexin A5 antibodies or Annexin A5 resistance | None (single-group prevalence) | Prevalence of IgM anti-Annexin A5 antibodies Studies of adults with APS and controls · Thrombosis type: Mixed | Pooled prevalence (%) 7.0 [2.8, 12.7] GRADE not reported 21 studies · 1746 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 5.92 [2.16, 16.19] GRADE not reported 16 studies · 767 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 5.11 [2.64, 9.89] GRADE not reported 35 studies · 1963 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 1 | AOR 1.18 [0.20, 7.07] GRADE not reported 16 studies · 767 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 2 | AOR 2.48 [0.38, 16.20] GRADE not reported 16 studies · 767 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 12.89 [1.51, 110.30] GRADE not reported 2 studies · 136 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 4.68 [1.22, 17.91] GRADE not reported 35 studies · 1963 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 15.08 [2.22, 102.41] GRADE not reported 2 studies · 136 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 1.90 [0.56, 6.43] GRADE not reported 35 studies · 1963 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 10.82 [1.04, 112.24] GRADE not reported 13 studies · 637 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 8.36 [2.56, 27.30] GRADE not reported 13 studies · 637 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 9.46 [3.97, 22.53] GRADE not reported 21 studies · 1042 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 2.68 [0.09, 82.18] GRADE not reported 2 studies · 136 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 15.30 [0.17, 1371.11] GRADE not reported 2 studies · 136 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 13.05 [1.77, 96.06] GRADE not reported 21 studies · 1042 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 11.41 [1.55, 84.07] GRADE not reported 21 studies · 1042 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Sapporo or still birth | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 0.55 [0.00, 505.64] GRADE not reported 2 studies · 136 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.68 [0.67, 4.23] GRADE not reported 18 studies · 1974 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.83 [0.53, 6.37] GRADE not reported 9 studies · 1238 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 1.13 [0.01, 107.86] GRADE not reported 4 studies · 337 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 0.69 [0.24, 2.02] GRADE not reported 28 studies · 4169 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 3.16 [0.57, 17.33] GRADE not reported 4 studies · 337 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 2.34 [0.61, 9.03] GRADE not reported 28 studies · 4169 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 2 | AOR 1.47 [0.21, 10.39] GRADE not reported 18 studies · 1974 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 2.80 [0.41, 19.16] GRADE not reported 11 studies · 1810 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.52 [0.56, 4.15] GRADE not reported 11 studies · 1810 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 1 | AOR 0.45 [0.09, 2.16] GRADE not reported 18 studies · 1974 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 1.81 [0.13, 25.29] GRADE not reported 5 studies · 448 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 4.24 [0.55, 32.66] GRADE not reported 11 studies · 1810 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 11.69 [0.19, 704.89] GRADE not reported 5 studies · 448 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.17 [0.59, 2.30] GRADE not reported 28 studies · 4169 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 3.21 [0.37, 28.22] GRADE not reported 9 studies · 1238 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Other pregnancies (not Sapporo) | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 3.18 [0.79, 12.81] GRADE not reported 5 studies · 448 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 0.64 [0.22, 1.87] GRADE not reported 40 studies · 3184 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.93 [0.06, 15.12] GRADE not reported 1 study · 150 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.96 [0.37, 2.49] GRADE not reported 17 studies · 1707 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 3.14 [0.48, 20.57] GRADE not reported 22 studies · 1577 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.22 [0.64, 2.33] GRADE not reported 40 studies · 3184 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 1.78 [0.12, 25.86] GRADE not reported 5 studies · 672 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.66 [0.71, 3.88] GRADE not reported 22 studies · 1577 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 1 | AOR 0.31 [0.06, 1.49] GRADE not reported 17 studies · 1707 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 2.41 [0.39, 15.04] GRADE not reported 22 studies · 1577 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.94 [0.50, 7.50] GRADE not reported 5 studies · 672 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 8.84 [0.20, 382.19] GRADE not reported 5 studies · 672 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 1.56 [0.04, 58.43] GRADE not reported 1 study · 150 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 1.86 [0.52, 6.63] GRADE not reported 40 studies · 3184 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.19 [0.38, 3.74] GRADE not reported 13 studies · 1329 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 2 | AOR 0.91 [0.14, 6.04] GRADE not reported 17 studies · 1707 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Population type) | Thrombosis | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 2.73 [0.32, 23.58] GRADE not reported 13 studies · 1329 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | IgG | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 2.08 [1.30, 3.34] GRADE not reported 81 studies · 5971 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | IgG | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 2.47 [1.54, 3.97] GRADE not reported 81 studies · 5971 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | IgG | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.54 [0.07, 33.20] GRADE not reported 55 studies · 4445 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | IgG | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 2.55 [1.44, 4.52] GRADE not reported 81 studies · 5971 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | IgG/IgM/IgA | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 4.22 [2.15, 8.31] GRADE not reported 18 studies · 1437 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | IgG/IgM/IgA | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 4.29 [2.23, 8.29] GRADE not reported 18 studies · 1437 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | IgG/IgM/IgA | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 2.48 [0.11, 57.37] GRADE not reported 14 studies · 1143 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | IgG/IgM/IgA | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 3.38 [1.52, 7.51] GRADE not reported 18 studies · 1437 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | Unknown | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.78 [0.22, 2.70] GRADE not reported 6 studies · 317 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | Unknown | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.60 [0.14, 2.63] GRADE not reported 6 studies · 317 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | Unknown | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 0.66 [0.19, 2.36] GRADE not reported 6 studies · 317 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Biomarker) | Unknown | IgM | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.36 [0.01, 11.71] GRADE not reported 5 studies · 292 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Control-SLE | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 4.35 [0.68, 27.71] GRADE not reported 3 studies · 209 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Control-SLE | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 3.49 [0.66, 18.50] GRADE not reported 3 studies · 209 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Control-SLE | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 3.00 [0.83, 10.89] GRADE not reported 3 studies · 209 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Control-SLE | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 2.66 [0.29, 24.58] GRADE not reported 3 studies · 232 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Control-SLE | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 4.00 [0.65, 24.60] GRADE not reported 3 studies · 209 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Control-SLE | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 3.89 [0.93, 16.26] GRADE not reported 3 studies · 209 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Control-SLE | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 5.69 [0.77, 42.18] GRADE not reported 3 studies · 209 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Control-SLE | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 3.99 [0.43, 37.11] GRADE not reported 3 studies · 232 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Control-SLE | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 2 | AOR 5.65 [1.19, 26.78] GRADE not reported 3 studies · 209 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Control-SLE | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 3.33 [0.51, 21.87] GRADE not reported 3 studies · 232 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Mixed | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.46 [0.03, 7.01] GRADE not reported 10 studies · 1096 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Mixed | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.99 [1.08, 3.65] GRADE not reported 95 studies · 9121 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Mixed | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 3.19 [1.02, 9.94] GRADE not reported 30 studies · 3098 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Mixed | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.49 [0.16, 1.45] GRADE not reported 46 studies · 4234 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Mixed | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 2.27 [0.91, 5.69] GRADE not reported 46 studies · 4342 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Mixed | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 2 | AOR 0.28 [0.07, 1.06] GRADE not reported 46 studies · 4342 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Mixed | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 3.50 [1.43, 8.56] GRADE not reported 46 studies · 4234 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Mixed | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 5.13 [1.23, 21.42] GRADE not reported 10 studies · 1096 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Mixed | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.27 [0.11, 0.67] GRADE not reported 95 studies · 9121 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | Mixed | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 6.12 [0.86, 43.51] GRADE not reported 5 studies · 463 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | SLE | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 9.45 [2.00, 44.64] GRADE not reported 5 studies · 106 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | SLE | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 7.26 [0.73, 72.69] GRADE not reported 2 studies · 160 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | SLE | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 6.31 [0.44, 90.10] GRADE not reported 2 studies · 160 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | SLE | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 13.27 [2.38, 74.08] GRADE not reported 5 studies · 106 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | SLE | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 7.67 [2.47, 23.84] GRADE not reported 8 studies · 195 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 1: Mixed group includes RA, no autoimmune disease and mixed status)) | SLE | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 9.50 [2.56, 35.23] GRADE not reported 8 studies · 195 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Control-no autoimmune disease | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 2.94 [0.11, 79.14] GRADE not reported 1 study · 16 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Control-no autoimmune disease | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.18 [0.02, 1.56] GRADE not reported 7 studies · 307 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Control-no autoimmune disease | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.44 [0.14, 1.33] GRADE not reported 17 studies · 813 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Control-no autoimmune disease | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.85 [0.09, 8.41] GRADE not reported 2 studies · 65 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Control-no autoimmune disease | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.17 [0.02, 1.19] GRADE not reported 7 studies · 307 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Control-no autoimmune disease | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.27 [0.06, 1.34] GRADE not reported 10 studies · 506 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Mixed | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 4.92 [0.87, 27.81] GRADE not reported 6 studies · 553 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Mixed | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 3.07 [0.77, 12.26] GRADE not reported 10 studies · 1136 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Mixed | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 2.67 [1.03, 6.96] GRADE not reported 39 studies · 2560 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Mixed | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.81 [0.91, 3.60] GRADE not reported 74 studies · 5778 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Mixed | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.76 [0.69, 4.46] GRADE not reported 39 studies · 3186 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | Mixed | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 2.17 [0.67, 7.07] GRADE not reported 26 studies · 2076 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | No autoimmune disease | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.46 [0.45, 4.76] GRADE not reported 15 studies · 1869 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | No autoimmune disease | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 4.28 [0.49, 37.10] GRADE not reported 2 studies · 120 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | No autoimmune disease | Control-mixed | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 3.47 [0.15, 82.45] GRADE not reported 1 study · 70 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | No autoimmune disease | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.02 [0.45, 2.36] GRADE not reported 29 studies · 3538 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | No autoimmune disease | Control-mixed | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.19 [0.25, 5.63] GRADE not reported 9 studies · 1128 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Autoimmune disorder (panel 2: Mixed group includes SLE, RA and mixed status)) | No autoimmune disease | Control-mixed | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.88 [0.26, 3.00] GRADE not reported 12 studies · 1262 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.36 [0.03, 4.62] GRADE not reported 1 study · 107 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 0.66 [0.07, 6.22] GRADE not reported 8 studies · 252 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 2.65 [0.64, 10.98] GRADE not reported 14 studies · 480 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 1.55 [0.15, 16.18] GRADE not reported 8 studies · 252 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.61 [0.01, 39.34] GRADE not reported 3 studies · 503 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 1 | AOR 11.66 [1.52, 89.66] GRADE not reported 9 studies · 357 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 1.08 [0.00, 780.48] GRADE not reported 1 study · 107 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.68 [0.16, 2.89] GRADE not reported 3 studies · 503 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 9.35 [2.52, 34.72] GRADE not reported 9 studies · 357 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 1.07 [0.04, 31.32] GRADE not reported 3 studies · 503 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 1.27 [0.09, 18.44] GRADE not reported 6 studies · 204 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 5.25 [1.35, 20.41] GRADE not reported 8 studies · 252 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 4.96 [1.86, 13.19] GRADE not reported 14 studies · 480 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 2 | AOR 28.04 [3.71, 211.90] GRADE not reported 9 studies · 357 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 10.74 [1.93, 59.87] GRADE not reported 6 studies · 204 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seronegative | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 4.36 [1.06, 17.85] GRADE not reported 14 studies · 480 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 1 | AOR 4.35 [0.58, 32.79] GRADE not reported 9 studies · 545 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 9.79 [2.01, 47.73] GRADE not reported 4 studies · 296 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 4.80 [1.32, 17.37] GRADE not reported 33 studies · 1900 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 4.27 [1.23, 14.75] GRADE not reported 9 studies · 545 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 7.21 [2.77, 18.81] GRADE not reported 19 studies · 1018 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 4.56 [2.28, 9.15] GRADE not reported 33 studies · 1900 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 4.92 [1.14, 21.13] GRADE not reported 8 studies · 502 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 4.42 [0.22, 87.76] GRADE not reported 7 studies · 533 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 0.34 [0.02, 4.95] GRADE not reported 8 studies · 502 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 0.63 [0.07, 5.30] GRADE not reported 19 studies · 1018 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 1.47 [0.15, 13.99] GRADE not reported 19 studies · 1018 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 2 | AOR 8.96 [1.24, 64.85] GRADE not reported 9 studies · 545 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 2.98 [0.82, 10.86] GRADE not reported 33 studies · 1900 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 6.79 [2.13, 21.66] GRADE not reported 7 studies · 533 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 2.26 [0.06, 82.73] GRADE not reported 7 studies · 533 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Seropositive | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 12.25 [0.03, 4908.15] GRADE not reported 4 studies · 296 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 0.60 [0.09, 3.92] GRADE not reported 30 studies · 3305 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.88 [0.63, 5.57] GRADE not reported 24 studies · 2644 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 1.87 [0.06, 58.45] GRADE not reported 3 studies · 366 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.36 [0.73, 2.51] GRADE not reported 63 studies · 7384 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.19 [0.23, 6.25] GRADE not reported 3 studies · 366 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.46 [0.34, 6.21] GRADE not reported 3 studies · 366 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 1 | AOR 4.21 [0.84, 21.16] GRADE not reported 37 studies · 3814 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 1.86 [0.64, 5.45] GRADE not reported 63 studies · 7384 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 1.01 [0.15, 6.81] GRADE not reported 30 studies · 3305 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.79 [0.75, 4.26] GRADE not reported 30 studies · 3305 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 1.88 [0.16, 21.44] GRADE not reported 3 studies · 366 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 2 | AOR 6.67 [1.35, 32.92] GRADE not reported 37 studies · 3814 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 2.04 [0.84, 4.93] GRADE not reported 37 studies · 3814 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 1.67 [0.56, 4.97] GRADE not reported 63 studies · 7384 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.67 [0.03, 14.01] GRADE not reported 3 studies · 366 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Mixed | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 0.50 [0.06, 4.34] GRADE not reported 24 studies · 2644 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Year of data collection (median) | Control | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.99 [0.79, 1.25] GRADE not reported 20 studies · 1819 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Year of data collection (median) | Control | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.99 [0.94, 1.04] GRADE not reported 81 studies · 5971 participants |
| Measures of AnxA5 prevalence in APS patients and controls (APS status) | Year of data collection (median) | Control | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.00 [0.97, 1.04] GRADE not reported 149 studies · 12082 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | High ROB | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.72 [0.08, 6.39] GRADE not reported 2 studies · 66 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | High ROB | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.90 [0.03, 23.68] GRADE not reported 1 study · 24 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.03 [0.58, 1.82] GRADE not reported 46 studies · 3132 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.28 [0.06, 1.20] GRADE not reported 8 studies · 826 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.93 [0.06, 14.18] GRADE not reported 12 studies · 1409 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.20 [0.50, 2.85] GRADE not reported 22 studies · 1216 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 1.19 [0.08, 18.77] GRADE not reported 8 studies · 826 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.41 [0.13, 1.35] GRADE not reported 12 studies · 1409 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 2.59 [0.38, 17.56] GRADE not reported 12 studies · 1409 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.76 [0.62, 5.04] GRADE not reported 18 studies · 1108 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Validity of APS criteria) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.45 [0.66, 3.18] GRADE not reported 31 studies · 2150 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ascertainment using diagnostics) | High ROB | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 2.21 [0.62, 7.90] GRADE not reported 6 studies · 162 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ascertainment using diagnostics) | High ROB | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 6.71 [0.24, 190.46] GRADE not reported 1 study · 24 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ascertainment using diagnostics) | High ROB | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 2.49 [0.26, 24.01] GRADE not reported 2 studies · 48 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ascertainment using diagnostics) | High ROB | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.97 [0.19, 20.47] GRADE not reported 2 studies · 48 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ascertainment using diagnostics) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.37 [0.50, 3.74] GRADE not reported 30 studies · 1884 participants |
| Adults tested for anti-Annexin A5 antibodies or A5R (prevalence measures from APS cohorts and controls) | Ascertainment using diagnostics: Unclear | Ascertainment using diagnostics: Low ROB (reference) | Prevalence of Annexin A5 resistance (A5R) Sensitivity analysis, one study one effect (single studies and case-control data): Univariable meta-regression | OR 1.34 [0.13, 14.22] GRADE not reported 12 studies · 1017 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ascertainment using diagnostics) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.95 [0.55, 1.63] GRADE not reported 87 studies · 5498 participants |
| Adults tested for anti-Annexin A5 antibodies or A5R (prevalence measures from APS cohorts and controls) | Ascertainment using diagnostics: Unclear | Ascertainment using diagnostics: Low ROB (reference) | Prevalence of Annexin A5 resistance (A5R) Univariable meta-regression | OR 1.13 [0.14, 9.01] GRADE not reported 18 studies · 1699 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ascertainment using diagnostics) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.25 [0.56, 2.77] GRADE not reported 43 studies · 2926 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ascertainment using diagnostics) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.89 [0.40, 1.97] GRADE not reported 46 studies · 2544 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ruling out other causes) | High ROB | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.68 [0.25, 1.85] GRADE not reported 11 studies · 1666 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ruling out other causes) | High ROB | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.37 [0.24, 7.74] GRADE not reported 4 studies · 704 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ruling out other causes) | High ROB | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.80 [0.45, 7.13] GRADE not reported 7 studies · 440 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ruling out other causes) | High ROB | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 6.19 [0.79, 48.33] GRADE not reported 3 studies · 186 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ruling out other causes) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.08 [0.39, 3.00] GRADE not reported 29 studies · 1965 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ruling out other causes) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.22 [0.51, 2.91] GRADE not reported 45 studies · 3189 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ruling out other causes) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.11 [0.63, 1.97] GRADE not reported 90 studies · 5955 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ruling out other causes) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.34 [0.13, 14.22] GRADE not reported 12 studies · 1017 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ruling out other causes) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.88 [0.39, 2.02] GRADE not reported 47 studies · 2664 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Ruling out other causes) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.13 [0.14, 9.01] GRADE not reported 18 studies · 1699 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Consistency in diagnostic methods) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.75 [0.07, 7.96] GRADE not reported 2 studies · 120 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Consistency in diagnostic methods) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.76 [0.45, 1.28] GRADE not reported 75 studies · 4310 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Consistency in diagnostic methods) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.89 [0.11, 7.09] GRADE not reported 2 studies · 120 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Consistency in diagnostic methods) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.97 [0.36, 2.60] GRADE not reported 28 studies · 1583 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Consistency in diagnostic methods) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.78 [0.36, 1.68] GRADE not reported 43 studies · 2595 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Consistency in diagnostic methods) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.76 [0.35, 1.65] GRADE not reported 37 studies · 1833 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 2 | AOR 1.69 [0.84, 3.37] GRADE not reported 24 studies · 1892 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 0.16 [0.00, 5.37] GRADE not reported 6 studies · 769 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.80 [0.82, 3.96] GRADE not reported 24 studies · 1892 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 0.18 [0.02, 1.83] GRADE not reported 10 studies · 1352 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 3.69 [1.28, 10.69] GRADE not reported 13 studies · 984 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable | AOR 3.85 [1.40, 10.63] GRADE not reported 13 studies · 984 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.28 [0.09, 0.84] GRADE not reported 10 studies · 1352 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 2.35 [0.94, 5.90] GRADE not reported 16 studies · 1075 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 1.88 [0.89, 3.96] GRADE not reported 16 studies · 1075 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 2.35 [1.13, 4.89] GRADE not reported 16 studies · 1075 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): multivariable Model 1 | AOR 1.73 [0.84, 3.57] GRADE not reported 24 studies · 1892 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 1.31 [0.73, 2.35] GRADE not reported 37 studies · 2900 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.62 [0.03, 15.16] GRADE not reported 10 studies · 1352 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Data completeness) | Unclear | Low ROB | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.16 [0.04, 0.59] GRADE not reported 6 studies · 769 participants |
| Adults tested for anti-Annexin A5 antibodies or A5R (prevalence measures from APS cohorts and controls) | Sample size: ≥100 | Sample size: <100 (reference) | Prevalence of anti-Annexin A5 antibodies (any isotype) Sensitivity analysis, one study one effect (single studies and case-control data): Multivariable meta-regression, Model 2 (autoimmune disorder retained) | AOR 0.77 [0.38, 1.56] GRADE not reported 20 studies · 3707 participants |
| Adults tested for anti-Annexin A5 antibodies or A5R (prevalence measures from APS cohorts and controls) | Sample size: ≥100 | Sample size: <100 (reference) | Prevalence of Annexin A5 resistance (A5R) Sensitivity analysis, one study one effect (single studies and case-control data): Multivariable meta-regression | AOR 0.88 [0.03, 29.23] GRADE not reported 5 studies · 693 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Sample size) | ≥100 | <100 | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.49 [0.06, 3.88] GRADE not reported 8 studies · 1200 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Sample size) | ≥100 | <100 | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.31 [0.15, 0.65] GRADE not reported 16 studies · 3434 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Sample size) | ≥100 | <100 | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 2 | AOR 0.54 [0.34, 0.86] GRADE not reported 36 studies · 7487 participants |
| Adults tested for anti-Annexin A5 antibodies or A5R (prevalence measures from APS cohorts and controls) | Sample size: ≥100 | Sample size: <100 (reference) | Prevalence of Annexin A5 resistance (A5R) Sensitivity analysis, one study one effect (single studies and case-control data): Univariable meta-regression | OR 0.24 [0.05, 1.07] GRADE not reported 5 studies · 693 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Sample size) | ≥100 | <100 | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 0.27 [0.13, 0.54] GRADE not reported 16 studies · 3434 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Sample size) | ≥100 | <100 | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.37 [0.22, 0.64] GRADE not reported 36 studies · 7487 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Sample size) | ≥100 | <100 | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.24 [0.11, 0.55] GRADE not reported 16 studies · 3434 participants |
| Adults tested for anti-Annexin A5 antibodies or A5R (prevalence measures from APS cohorts and controls) | Sample size: ≥100 | Sample size: <100 (reference) | Prevalence of anti-Annexin A5 antibodies (any isotype) Sensitivity analysis, one study one effect (single studies and case-control data): Univariable meta-regression | OR 0.55 [0.25, 1.22] GRADE not reported 20 studies · 3707 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Sample size) | ≥100 | <100 | A5R prevalence (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 0.65 [0.10, 4.40] GRADE not reported 8 studies · 1200 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Sample size) | ≥100 | <100 | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Multivariable meta-regression Model 1 | AOR 0.47 [0.29, 0.75] GRADE not reported 36 studies · 7487 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Sample size) | ≥100 | <100 | A5R prevalence (meta-regression) Studies of adults with APS and controls · Univariable meta-regression | OR 0.30 [0.10, 0.91] GRADE not reported 8 studies · 1200 participants |
| Adults tested for anti-Annexin A5 antibodies or A5R (prevalence measures from APS cohorts and controls) | Sample size: ≥100 | Sample size: <100 (reference) | Prevalence of anti-Annexin A5 antibodies (any isotype) Sensitivity analysis, one study one effect (single studies and case-control data): Multivariable meta-regression, Model 1 (autoimmune disorder excluded) | AOR 0.67 [0.33, 1.38] GRADE not reported 20 studies · 3707 participants |
| Adults tested for anti-Annexin A5 antibodies or A5R (prevalence measures from APS cohorts and controls) | Sample size: ≥100 | Sample size: <100 (reference) | Prevalence of IgG anti-Annexin A5 antibodies Sensitivity analysis, one study one effect (single studies and case-control data): Multivariable meta-regression | AOR 0.38 [0.16, 0.92] GRADE not reported 14 studies · 2796 participants |
| Adults tested for anti-Annexin A5 antibodies or A5R (prevalence measures from APS cohorts and controls) | Sample size: ≥100 | Sample size: <100 (reference) | Prevalence of IgG anti-Annexin A5 antibodies Sensitivity analysis, one study one effect (single studies and case-control data): Univariable meta-regression | OR 0.37 [0.14, 1.03] GRADE not reported 14 studies · 2796 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Year of data collection (median)) | Year of data collection (median) | per additional year (median year of data collection) | A5R prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.94 [0.72, 1.23] GRADE not reported 14 studies · 1137 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Year of data collection (median)) | Year of data collection (median) | per additional year (median year of data collection) | AnxA5-Abs prevalence, any isotype (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 1.01 [0.96, 1.06] GRADE not reported 75 studies · 5923 participants |
| Measures of AnxA5 prevalence in APS patients and controls (Year of data collection (median)) | Year of data collection (median) | per additional year (median year of data collection) | IgG AnxA5-Abs prevalence (meta-regression) Studies of adults with APS and controls · Sensitivity (one study per effect): univariable | OR 0.98 [0.93, 1.04] GRADE not reported 55 studies · 4445 participants |
Included primary studies 62
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Zhang 2017 matched by author and year (probable) | NR | 2 other reviews | not stated | not extracted yet |
| Ferreira 2020 matched by author and year (probable) | NR | 1 other review | not stated | not extracted yet |
| Singh 2013 matched by author and year (probable) | NR | 1 other review | not stated | not extracted yet |
| Akhter 2012 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Akinshina 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Anunciación-Llunell 2022 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Arnold 2001 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Avriel 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Becarevic 2008 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Becarevic 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Bećarević 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Becarevic 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Bećarević 2018 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Bizzaro 2005 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Carmel-Neiderman 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Conti 2012 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Conti 2014 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Eschwege 1998 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Eschwège 1998 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Garcia 2010 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| GarciaRui 2010 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Gaspersic 2003 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Gaspersic 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Gašperšič 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Gris 2000 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Hu 2021 Significant decrease in hemoglobin and hematocrit levels in a virologically controlled HIV-infected patient. Pure red cell aplasia (PRCA)… PMID:12741369 | 2003 | this review only | not stated | not extracted yet |
| Hunt 2011 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ilan Volkov 2020 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ishikura 2004 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Kaburaki 1995 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Kaburaki 1997 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Khizroeva 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Khogeer 2021 [Working devices in severe wrist deformities]. PMID:5145526 | 1971 | this review only | not stated | not extracted yet |
| Liu 2022 The passage of certain substances out of the cerebrosphinal fluid. PMID:13972012 | 1963 | this review only | not stated | not extracted yet |
| Malickova 2013 ["Military Medicine and Unit Care in the Theater of War in Bulgaria and in the Rear of the Field Army in 1877--1878" by N. I. Pirogov (on… PMID:371101 | 1979 | this review only | not stated | not extracted yet |
| Maneyro 2015 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mekinian 2016 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mtiraoui 2007 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Mu 2024 A Platform for Rehabilitation of Finger Individuation in Children with Hemiplegic Cerebral Palsy. PMID:31374653 | 2019 | this review only | not stated | not extracted yet |
| Murad 2023 [Treatment of certain precancerous diseases and of cancer of the lower lip and of the face with Gordeev's solution]. PMID:13122322 | 1953 | this review only | not stated | not extracted yet |
| Nojima 2001 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ogawa 2000 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Park 2019 P3 latency determination by global field power in normal subjects. PMID:2019653 | 1991 | this review only | not stated | not extracted yet |
| Pelusa 2013 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Pelusa 2017 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Peluso 2007 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Rand 2006 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Rezk 2010 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Rigano 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Roldan 2002 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Roldán 2002 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Roselli 2023 Total health; a conceptual visual aid. PMID:13152507 | 1954 | this review only | not stated | not extracted yet |
| Satoh 1999 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Skare 2014 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Tang 2011 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Thaler 2019 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Tomer 2007 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ulcova-Gallova 2006 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Ulcová-Gallová 2006 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Wolgast 2010 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Wolgast 2012 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
| Zammiti 2006 matched by author and year (probable) | NR | this review only | not stated | not extracted yet |
Overlap with other reviews
Reviews that include the same primary studies are not independent evidence. Shared counts match studies by PMID, DOI or NCT, and otherwise by author and year (a probable match). Only the non-Cochrane dental reviews have study lists, so overlap with Cochrane reviews is not counted yet.
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Adults (18 years or older) tested for AnxA5-Abs (IgG/IgM) and/or A5R who fulfil revised Sapporo/Sydney APS clinical criteria; predefined subgroup of women with unexplained pregnancy loss | 58 studies, 6960 patients and 2417 controls (169 stratified prevalence measures) |
| Intervention | Not applicable (prevalence review of AnxA5-Abs and A5R testing) | Not applicable |
| Comparison | Controls where reported | Controls (healthy, disease, SLE, RA) |
| Outcomes | Prevalence of AnxA5-Abs (IgG, IgM) and A5R; association with thrombotic and obstetric manifestations | Pooled prevalence of IgG AnxA5-Abs, IgM AnxA5-Abs, IgG/IgM/IgA, A5R; meta-regression ORs |
| Study designs | Observational studies; case reports, case series, editorials, narrative reviews, animal and in vitro studies excluded | 58 observational studies (mostly cross-sectional), 1995-2024 |
| Timing | Not specified | Not specified |